Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardant HealthGH -1.36%65 3-Year EBITDA Growth Rate is 20.90% as of Jun. 2026. GuruFocus rates GH with a GF Score™ of 65/100 and a GF Value™ of $65.63 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Guardant Health ranks better than 64.85% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Guardant Health was 20.90% per year. The lowest was -112.10% per year. And the median was -12.50% per year.
Guardant Health (NAS:GH) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Guardant Health 3-Year EBITDA Growth Rate Related Terms
GH vs MEDP, LH, DGX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Guardant Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Guardant Health's 3-Year EBITDA Growth Rate falls into.
Guardant Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.90% mean?
Guardant Health (GH) has a 3-Year EBITDA Growth Rate of 20.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #58 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 35.2%.
Is Guardant Health's 3-Year EBITDA Growth Rate too high?
Guardant Health's current 3-Year EBITDA Growth Rate is 20.90%. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. Guardant Health's value of 20.90% is 90% above this industry median. Based on the distribution chart, Guardant Health ranks #58 out of 165 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Guardant Health has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's 3-Year EBITDA Growth Rate compare to MEDP and LH?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #58 out of 165 companies for 3-Year EBITDA Growth Rate. This puts Guardant Health in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. Guardant Health's value of 20.90% is 90% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guardant Health's current 3-Year EBITDA Growth Rate of 20.90% is 90% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Guardant Health and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardant Health's current 3-Year EBITDA Growth Rate is 20.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (GH) is currently considered Significantly Overvalued. The stock's GF Value™ is $65.63, compared to a current price of $168.52 — trading 156.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.90% and 90% above the Medical Diagnostics & Research industry median of 11.00. Guardant Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Guardant Health (GH), the current 3-Year EBITDA Growth Rate is 20.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of $168.52 is trading 156.8% above its estimated GF Value™ of $65.63.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for GH:
3-Year EBITDA Growth Rate: 20.90%
GF Value™: $65.63 vs. price of $168.52 (156.8% above fair value)
Industry Position: 90% above the Medical Diagnostics & Research median (#58 of 165)
No single metric tells the full story. See the GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
65GF Score
Get the complete analysis for GH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GH has been successfully added to your 
